Impact of discrepant results from clinical laboratories on patients and pharmaceutical trials: Evidence from proficiency testing results

Biomarkers in Medicine

Volumn 3, Issue 3, 2009, Pages 231-238

  Halim, Abdel Basit ^a  

^a DAIICHI SANKYO INC   (United States)

Author keywords

Digoxin; Discrepant laboratory results; INR; LDL C; Pharmaceutical trials; Risk

Indexed keywords

BIOLOGICAL MARKER; DIGOXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CLINICAL LABORATORY; DECISION MAKING; DRUG INDUSTRY; DRUG RESEARCH; GOOD LABORATORY PRACTICE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; QUALITY CONTROL; STANDARDIZATION;

EID: 67949088261     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.09.16     Document Type: Article

References (27)

1. Kalra J: Medical errors - impact on clinical laboratories and other critical areas. Clin. Biochem. 37, 1052-1062 (2004).
2. Stankovic AK, Romeo P: The role of in vitro diagnostic companies in reducing laboratory error. Clin. Chem. Lab. Med. 45, 781-788 (2007).
3. Carraro P, Plebani M: Errors in a stat laboratory: types and frequencies 10 years later. Clin. Chem. 53, 1338-1342 (2007).
4. Bremond J, Plebani M: IVD industry role for quality and accreditation in medical laboratories. Clin. Chim. Acta 309, 167-171 (2001).
5. Stankovic AK: The laboratory is a key partner in assuring patient safety. Clin. Lab. Med. 24, 1023-1035 (2004).
6. Plebani M: Errors in clinical laboratories or errors in laboratory medicine? Clin. Chem. Lab. Med. 44, 750-759 (2006).
7. Burnett D, Blair C: Standards for the medical laboratory-harmonization and subsidiarity. Clin. Chim. Acta 309, 137-145 (2001).
8. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
9. Ismail AA, Walker PL, Barth JH, Lewandowski KC, Jones R, Burr WA: Wrong biochemistry results: two case reports and observational study in 5310 patients on potentially misleading thyroid-stimulating hormone and gonadotropin immunoassay results. Clin. Chem. 48, 2023-2029 (2002).
10. Hirsh J, Fuster V, Ansell J, Halperin JL: American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. Circulation 107, 1692-1711 (2003).
11. Roberts GW, Adams R: Impact of introducing anticoagulation-related prescribing guidelines in a hospital setting using academic detailing. Ther. Clin. Risk Manag. 2, 309-316 (2006).
12. Franke CA, Dickerson LM, Carek PJ: Improving anticoagulation therapy using point-of-care testing and a standardized protocol. Ann. Fam. Med. 6, S28-32 (2008).
13. Horsti J, Helena Uppa H, A Vilpo J: Poor agreement among prothrombin time international normalized ratio methods: comparison of seven commercial reagents. Clin. Chem. 51, 553-560 (2005)
14. Caprini JA, Arcelus JI, Motykie G, Kudrna JC, Mokhtee D, Reyna JJ: The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement. J. Vasc. Surg. 30, 813-820 (1999).
15. Hirsh J, Dalen J, Anderson DR et al.: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119, S8-S21 (2001).
16. Morris SA, Hatcher HF, Reddy DK: Digoxin therapy for heart failure: an update. Am. Fam. Physician 74, 613-618 (2006).
17. Valdes R Jr, Jortani SA, Gheorghiade M: Standards of laboratory practice: cardiac drug monitoring. National Academy of Clinical Biochemistry. Clin. Chem. 44, 1096-1109 (1998)
18. Gheorghiade M, van Veldhuisen DJ, Colucci WS: Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 113, 2556-2564 (2006).
19. Tuncok Y, Hazan E, Oto O, Guven H, Catalyurek H, Kalkan S: Relationship between high serum digoxin levels and toxicity. Int. J. Clin. Pharmacol. Ther. 35, 366-368 (1997).
20. Aronson JK, Grahame-Smith DG, Wigley FM: Monitoring digoxin therapy. The use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity. Q. J. Med. 47, 111-122 (1978).
21. Howanitz PJ, Steindel SJ: Digoxin therapeutic drug monitoring practices. A College of American Pathologists Q-Probes study of 666 institutions and 18,679 toxic levels. Arch. Pathol. Lab. Med. 117, 684-690 (1993).
22. Cheng AY, Leiter LA: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr. Opin. Cardiol. 21, 400-404 (2006).
23. Grundy SM, Cleeman JI, Merz CN et al.; Coordinating Committee of the National Cholesterol Education Program: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler. Thromb. Vasc. Biol. 24, E149-E161 (2004).
24. Grundy SM, Cleeman JI, Merz CN et al.; Coordinating Committee of the National Cholesterol Education Program: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J. Am. Coll. Cardiol. 44, 720-732 (2004).
25. Aronow WS: Treatment of high-risk older persons with lipid-lowering drug therapy. Am. J. Ther. 15, 102-107 (2008).
26. Miller G: International lipoprotein standardization. Presented at: Annual Meeting of the American Association for Clinical Chemistry. Washington Convention Center, Washington, DC, USA, 29-31 July 2008.
27. Miller WG, Waymack PP, Anderson P, Ethridge SF, Jayne EC: Performance of four homogeneous direct methods for LDL-cholesterol. Clin. Chem. 48, 489-498 (2002).